

Free Fatty Acid-Induced Inhibition of Glucose and Insulin-Like Growth Factor I-Induced Deoxyribonucleic Acid Synthesis in the Pancreatic β -Cell Line INS-1*

SHARON P. COUSIN, SIGRUN R. HÜGL, CHRISTIAN E. WREDE, HIROSHI KAJIO, MARTIN G. MYERS, JR., AND CHRISTOPHER J. RHODES

Pacific Northwest Research Institute, and Department of Pharmacology, University of Washington, Seattle, Washington 98122; and Research Division, Joslin Diabetes Center (M.G.M.), Boston, Massachusetts 02215

ABSTRACT

Pancreatic β -cell mitogenesis is increased by insulin-like growth factor I (IGF-I) in a glucose-dependent manner. In this study it was found that alternative β -cell nutrient fuels to glucose, pyruvate, and glutamine/leucine independently induced and provided a platform for IGF-I to induce INS-1 cell DNA synthesis in the absence of serum. In contrast, long chain FFA ($\geq C_{12}$) inhibited 15 mM glucose-induced [3H]thymidine incorporation (± 10 nM IGF-I) by 95% or more within 24 h above 0.2 mM FFA complexed to 1% BSA ($K_{0.5}$ for palmitate/1% BSA = 65–85 μM for 24 h; $t_{0.5}$ for 0.2 mM palmitate/1% BSA = ~6 h). FFA-mediated inhibition of glucose/IGF-I-induced β -cell DNA synthesis was reversible, and FFA oxidation did not appear to be required, nor did FFA interfere with glucose metabolism in INS-1 cells.

An examination of mitogenic signal transduction pathways in INS-1 cells revealed that glucose/IGF-I induction of early signaling elements in SH2-containing protein (Shc)- and insulin receptor substrate-1/2-mediated pathways leading to downstream mitogen-activated protein kinase and phosphoinositol 3'-kinase activation, were unaffected by FFA. However, glucose/IGF-I-induced activation of protein kinase B (PKB) was significantly inhibited, and protein kinase C ζ was chronically activated by FFA. It is possible that FFA-mediated inhibition of β -cell mitogenesis contributes to the reduction of β -cell mass and the subsequent failure to compensate for peripheral insulin resistance *in vivo* that is key to the pathogenesis of obesity-linked diabetes. (*Endocrinology* 142: 229–240, 2001)

PANCREATIC β -CELL proliferation can be increased by several growth factors and certain nutrients (1, 2). However, it has not been until relatively recently that intracellular mitogenic signal transduction pathways, downstream of a growth factor receptor, have been investigated in pancreatic β -cells (3, 4). Insulin-like growth factor I (IGF-I), via activation of the intrinsic tyrosine kinase activity of the IGF-I receptor, tyrosine phosphorylates SH2-containing protein (SH2), insulin receptor substrate-1 (IRS-1), and IRS-2, resulting in downstream activation of mitogen-activated protein kinase [MAPK; extracellular regulated kinase-1 (Erk-1) and -2 isoforms], phosphatidylinositol 3'-kinase (PI3'K), and p70^{S6K} (5). GH predominately signals via Janus kinase-2 (JAK2)/signal transducer and activator of transcription-5 (STAT5) activation, and in pancreatic β -cells there is no cross-talk to IRS-mediated signal transduction pathways (4). Unusually, and probably somewhat unique to the pancreatic β -cell, both GH and IGF-I are dependent on glucose being present in the physiologically relevant range (6–18 mM) to exert a mitogenic effect (3, 4). Intriguingly, glucose (>6 mM) is capable of independently activating IRS-1/2-mediated signal transduction (3, 4), but not JAK2/STAT5 signaling, despite GH-induced β -cell DNA synthesis being

glucose dependent (4). However, the means by which glucose provides a permissive platform for IGF-I- and GH-induced β -cell mitogenesis is essentially unknown, other than that glucose metabolism is necessary (3, 4). In part this study examines whether other nutrient fuels, alternative to glucose, can provide a similar permissive basis for IGF-I- and GH-induced β -cell mitogenesis.

In states of peripheral insulin resistance, such as obesity, an increased demand for insulin can be compensated for by an increase in β -cell mass and relatively increased insulin production (6, 7). However, when pancreatic β -cell mass does not increase, there is a failure to compensate for the insulin resistance, and obesity-linked type II diabetes ensues (8). Thus, control of β -cell growth is a key factor contributing to the pathogenesis of type II diabetes. IRS-mediated signal transduction is important for glucose- and glucose-dependent growth factor-induced β -cell DNA synthesis, especially that via IRS-2 and PI3'K (3, 9). Moreover, it has been demonstrated that IRS-mediated mitogenic signal transduction pathways in the β -cell could play an important role in the pathogenesis of type II diabetes (10, 11). In the IRS-1 knockout mouse there is peripheral insulin resistance that is compensated for by an increase in β -cell mass, and there is no diabetes (10). However, in the IRS-2 knockout mouse the β -cell mass is markedly reduced, and in the face of additional peripheral insulin resistance, type II diabetes ensues (10, 11). Although there are likely genetic susceptibilities involved in the pathogenesis of type II diabetes (12), it appears that alterations in the IRS-2 primary gene structure do not contribute (13). However, this does not rule out that adverse

Received June 1, 2000.

Address all correspondence and requests for reprints to: Christopher J. Rhodes, Ph.D., Pacific Northwest Research Institute, 720 Broadway, Seattle, Washington 98122. E-mail: cjr@pnri.org.

* This work was supported by grants from the NIH (GK-55267), the Juvenile Diabetes Foundation International, the German Research Society, and BetaGene, Inc.

biochemical affects in IRS-2 function could lead to a diabetic state. As such, an unresolved question is what are the pathophysiological factors that prevent an increase and/or decrease β -cell mass in type II diabetes so that there is no longer compensation for peripheral insulin resistance. It is thought that both prolonged hyperglycemia and hyperlipidemia are such contributing factors, and they can be detrimental to β -cell function and mass (6–8, 14).

In general, glucose has a tendency to increase β -cell mitogenesis (1, 2). In this study an examination of alternative nutrient fuels that might increase β -cell growth similar to the effect of glucose found that long chain FFA inhibited glucose-induced and glucose-dependent IGF-I-induced β -cell DNA synthesis. This in part was attributed to interference by FFAs in IRS-mediated signal transduction pathways downstream of PI3'-K. It is postulated that exposure to FFA leads to a reduction in β -cell mitogenesis as well as peripheral insulin resistance (7, 15, 16) that would contribute to decreased β -cell mass *in vivo* and presentation of type II diabetes.

Materials and Methods

Materials

[methyl- 3 H]Thymidine (20 Ci/mmol) was obtained from NEN Life Science Products (Boston, MA), and [γ - 32 P]ATP (3000 Ci/mmol) was obtained from Amersham Pharmacia Biotech (Piscataway, NJ). Anti-active phospho-MAPK (Erk1/2), phospho-p38, phospho-c-Jun N-terminal kinase-1/2 (JNK1/2), as well as anti-total MAPK (Erk1/2), p38, and JNK1/2 antisera were purchased from Promega Corp. (Madison, WI). The IRS-1 and IRS-2 antisera were generated as previously described (17). The p70^{S6K} antisera were generated and used in immunoblot analysis as previously described (18). Anti-PI3'-K p85, protein kinase B (PKB), mammalian Son of Sevenless (mSOS), growth factor bound protein 2 (Grb2), Shc, and antiphosphotyrosine antisera were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Anti-protein kinase C ζ (anti-PKC ζ) antisera was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The PKB activity assay kit was purchased from New England Biolabs, Inc. (Beverly, MA), and [Ser¹⁵⁹]PKC ϵ -(153–164)-NH₂ PKC peptide substrate was obtained from Upstate Biotechnology, Inc. L- α -Phosphatidylserine and L- α -phosphatidylinositol were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL), 2-bromopalmitate was obtained from Aldrich Chemical Co., Inc. (Milwaukee, WI), methyl-palmitate was purchased from Sigma (St. Louis, MO), and all other FFA were purchased from Alltech (Deerfield, IL). FFA-free BSA was obtained from Roche Molecular Biochemicals (Indianapolis, IN), and C2 ceramide, N-acetyl-D-erythro-sphingosine, dihydro-N-acetyl-D-erythro-sphingosine, as well as IGF-I were purchased from Calbiochem-Novabiochem (La Jolla, CA). Transblot nitrocellulose membrane (0.2- μ m pore size) were obtained from Bio-Rad Laboratories, Inc. (Hercules, CA). The immunoblot chemiluminescence detection kit was obtained from NEN Life Science Products (Boston, MA). Unless otherwise stated all other biochemicals were purchased from either Sigma (St. Louis, MO) or Fisher Scientific (Pittsburgh, PA) and were of the highest purity available.

Cell culture

The glucose-sensitive pancreatic β -cell line, INS-1 (19), was used in the experiments. INS-1 cells were maintained in RPMI 1640 medium containing 2 mM L-glutamine, 1 mM sodium pyruvate, 50 μ M β -mercaptoethanol, 100 U/ml penicillin, 100 μ g/ml streptomycin, 10% FCS, and 11.2 mM glucose and incubated at 37°C in 5% CO₂ as previously described (19). Cells were subcultured at 80% confluence.

FFA/BSA complex solution preparation

A 100-mM FFA stock solution was prepared in 0.1 M NaOH by heating at 70°C in a shaking water bath. In an adjacent water bath at 55°C, a 10% (wt/vol) FFA-free BSA solution was prepared in H₂O. Altering the proportion of these two solutions when mixed together varied the concentration of FFA complexed to BSA. For example, a 5-mM FFA/10%

BSA stock solution was prepared by adding 50 μ l of the 100 mM FFA solution dropwise to 950 μ l 10% BSA solution at 55°C in a shaking water bath, then vortex mixed for 10 sec followed by a further 10-min incubation at 55°C. The FFA/BSA complexed solution is cooled to room temperature and sterile filtered (0.45- μ m pore size membrane filter). It can be stored at -20°C, where it is stable for 3–4 weeks. Stored 5-mM FFA/10% BSA stock solutions are heated for 15 min at 55°C, then cooled to room temperature before use.

[3 H]Thymidine incorporation

Incorporation of [3 H]thymidine was used as an indicator of DNA synthesis and INS-1 cell mitogenesis (20). A 96-well plate [3 H]thymidine assay was used as previously described (3, 4). Essentially, INS-1 cells were cultured on 96-well plates and incubated at 37°C in INS-1 medium to a density of approximately 2.5×10^4 cells/well. The medium was removed, and the cells were made quiescent by serum and glucose deprivation for 24 h in RPMI 1640 containing 0.1% BSA instead of serum and 0.5 mM glucose. The INS-1 cells were then incubated for a further 24 h in RPMI 1640 and 0.1% BSA at different glucose concentrations (0–24 mM glucose) with or without IGF-I (10 nM) and FFA (0.02–0.5 mM) complexed to 1% BSA. The last 4 h of this latter incubation period was carried out in the additional presence of 5 μ Ci [3 H]thymidine/ml to monitor the degree of DNA synthesis and assess the β -cell mitogenesis rate. After this final incubation period, the cells were centrifuged ($3000 \times g$, 10 min, 4°C: Sorvall RT7 centrifuge (DuPont Medical Products, Newtown, CT) and RT750 rotor and 96-well plate holders), washed, and lysed using a semiautomatic cell harvester (Packard Instrumentation, Meriden, CT), and the cell lysates were transferred to Whatman glass-fiber micropore filters (Clifton, NJ). The [3 H]thymidine specifically incorporated into the INS-1 cell DNA trapped on glass-fiber filters was counted by liquid scintillation counting.

Protein immunoblot and coimmunoprecipitation analysis

INS-1 cells were subcultured on 10-cm plates to about 70% confluence as previously described (19). The cells were then incubated for a 24-h period of quiescence by serum and glucose deprivation in RPMI 1640 medium containing 0.1% BSA instead of serum and 0.5 mM glucose with or without 0.2–0.4 mM FFA complexed to 1% BSA. INS-1 cells were then incubated in fresh RPMI 1640 medium containing 0, 3, or 15 mM glucose with or without 10 nM IGF-I and 0.2–0.4 mM FFA/1% BSA for between 5 and 30 min as indicated. The cells were lysed in 0.5 ml ice-cold lysis as previously described (3, 4). Immunoprecipitation and immunoblot analysis of mitogenic signal transduction protein expression and protein tyrosine phosphorylation were performed as previously described (3, 4).

PI3'-K assay

PI3'-K was assayed as previously described (21, 22). Essentially, INS-1 cells were incubated at 0, 3, or 15 mM glucose with or without 10 nM IGF-I and 0.4 mM FFA/1% BSA for 15 min, then PI3'-K was immunoprecipitated from 750 μ g total protein of cell lysate with an anti-PI3'-K p85 antibody. The immunoprecipitates were washed twice in 300 μ l PBS (pH 7.4), 1% Nonidet P-40, and inhibitor cocktail (containing 1 mM Na₃VO₄, 20 mM NaF, 10 mM sodium pyrophosphate, 1 mM EDTA, 10 μ M leupeptin, 10 μ g/ml aprotinin, and 100 μ M phenylmethylsulfonylfluoride); twice with 300 μ l 0.1 M Tris-HCl (pH 7.5), 0.5 M LiCl, and inhibitor cocktail; and finally twice with 300 μ l 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, and inhibitor cocktail. Immunoprecipitates were then suspended in 70 μ l 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA, 100 μ M Na₃VO₄, and 100 μ M 15 mM MgCl₂ containing 20 μ g L- α -phosphatidylinositol. The assay was initiated by addition of 5 μ l 10 mM Tris-HCl (pH 7.5), 20 mM MgCl₂, and 1 mM ATP containing 20 μ Ci [γ - 32 P]ATP and incubated for 10 min at 30°C in a shaking water bath. The reaction was stopped by addition 20 μ l 8 M HCl, and the phospholipids were chloroform/methanol (1:1) extracted. [32 P]Phospholipids were then separated by TLC and detected by autoradiography as previously described (21, 22). Quantification of the phosphatidylinositol-3'-[32 P]phosphate produced was determined by densitometric scanning of the autoradiographs.

PKB assay

PKB activity was determined using a kit provided by New England Biolabs, Inc. Essentially, INS-1 cells were incubated as described for the

PI3'-K assay described above. PKB was immunoprecipitated from 1 mg total protein equivalent of cell lysate with anti-PKB antibody linked to agarose beads overnight at 4°C with rotary mixing. Agarose beads were then pelleted by centrifugation ($10,000 \times g$, 30 sec, 4°C), and the supernatant was removed. Immunoprecipitates were then washed twice in 500 μ l ice-cold lysis buffer, then twice with 500 μ l ice-cold PKB assay buffer consisting of 25 mM Tris (pH 7.5), 5 mM β -glycerophosphate, 2 mM dithiothreitol, 100 μ M mM Na_3VO_4 , and 10 mM MgCl_2 containing 20 μ g $\text{L-}\alpha$ -phosphatidylinositol. PKB immunoprecipitates were suspended in 40 μ l assay buffer additionally containing 200 μ M ATP and 1 μ g glycogen synthase-kinase (GSK)-3 α / β fusion protein (containing the Ser^{21/9} phosphorylation site), then incubated for 20 min at 30°C in a shaking water bath. The reaction was stopped by the addition of 20 μ l 3 \times SDS-electrophoresis sample buffer and then heated at 95°C for 5 min. The sample was run on SDS-PAGE, and the extent of GSK3 phosphorylation was analyzed with a specific phospho-GSK-3 antibody.

PKC ζ assay

PKC ζ activity was determined as previously described (23). Essentially, INS-1 cells were incubated as described for the PI3'-K assay described above. PKC ζ was then immunoprecipitated from 750 μ g total protein equivalent of lysate (in a 500- μ l final volume) with an anti-PKC ζ antibody, followed by protein A-Sepharose as described previously (3, 4). Immunoprecipitates were then washed twice in 500 μ l ice-cold lysis buffer, then twice with 500 μ l ice-cold assay buffer consisting of 20 mM HEPES (pH 7.5), 1 mM Na_3VO_4 , 20 mM NaF, 10 mM sodium pyrophosphate, 1 mM EDTA, 10 μ M leupeptin, 10 μ g/ml aprotinin, and 100 μ M phenylmethylsulfonylfluoride. PKC ζ immunoprecipitates were then suspended in 50 μ l of the assay buffer, additionally containing 40 μ M [Ser¹⁵⁹]PKC- ϵ (153-164)-NH₂ peptide substrate, 50 μ M ATP, and 40 μ g/ml phosphatidylserine. The reaction was started by the addition of 5 μ Ci [γ -³²P]ATP and was incubated for 10 min at 30°C in a shaking water bath. A 25- μ l aliquot of reaction mixture was then spotted onto a phosphocellulose p81 filter (Whatman) presoaked in 10% (vol/vol) acetic acid to trap the [Ser¹⁵⁹]PKC- ϵ (153-164)-NH₂ peptide substrate. The filters were immediately extensively washed in 10% acetic acid by flow-through on a sample manifold apparatus (Millipore Corp., Bedford,

MA), followed by repeated washes for an additional 10 min. The filters were then air-dried. Quantification of [³²P]Ser¹⁵⁹PKC- ϵ (153-164)-NH₂ peptide was performed by liquid scintillation counting.

Other procedures

Protein assay was by the bicinchoninic acid method (Pierce Chemical Co., Rockford, IL). Data are presented as the mean \pm SE, with the number of individual observations indicated (n). Statistically significant differences between groups were analyzed using Student's *t* test, where *P* < 0.05 was considered statistically significant.

Results

Alternative nutrient fuels stimulate β -cell DNA synthesis

The effects of pyruvate, leucine, and α -ketoisocaproate, all established nutrient fuels of pancreatic β -cells (24), on INS-1 cell DNA synthesis (with or without 10 nM IGF-I) was determined by [³H]thymidine incorporation. INS-1 cells were chosen as a model to examine β -cell mitogenesis, because they respond to glucose in the physiologically relevant range (6–18 mM glucose) (3, 4, 19). A 15-mM glucose concentration significantly increased [³H]thymidine incorporation in INS-1 cells between 20- to 25-fold above baseline (*P* \leq 0.001; Figs. 1–3). In the absence of glucose, IGF-I (10 nM) had no effect on INS-1 cell DNA synthesis and had a modest 3- to 4-fold increase at 3 mM glucose (*P* \leq 0.05), but had a marked significant 50- to 60-fold increase at a stimulatory 15 mM glucose (Figs. 1–3; *P* \leq 0.001), as previously observed (3, 4). The [³H]thymidine incorporation assay was used as a marker of INS-1 cell mitogenesis. Cell counting revealed that a 20-fold increase in [³H]thymidine incorporation in a 24-h period, as instigated by 15 mM glucose, was equivalent to a




FIG. 1. Alternative metabolic fuels can stimulate DNA synthesis in INS-1 cells. DNA synthesis was determined at 0, 3, or 15 mM glucose with or without 10 nM IGF-I (as controls) or in the presence of alternative fuels [including 1 and 5 mM pyruvate with or without 1 mM α -cyano-4-hydroxycinnamate (α -CHC), 10 mM glutamine, 10 mM leucine, 10 mM glutamine and 10 mM leucine, or 10 mM α -ketoisocaproate (α -KIC)] using a [³H]thymidine incorporation assay as described in *Materials and Methods*. All experiments were performed in triplicate on at least six independent occasions. The data are expressed as the fold increase above the control observation in the absence of glucose and IGF-I and are depicted as the mean \pm SE (n = 6).

2-fold increase in cell number. A 50-fold increase in $[^3\text{H}]$ thymidine incorporation within 24 h, as stimulated by 15 mM glucose and 10 nM IGF-I increased cell number 3- to 4-fold.

Pyruvate (1 or 5 mM) independently increased INS-1 cell $[^3\text{H}]$ thymidine incorporation between 8- to 10-fold ($P \leq 0.01$), and between 25- to 28-fold in the added presence of 10 nM IGF-I ($P \leq 0.001$; Fig. 1). The addition of 1 mM α -cyano-4-hydroxycyanocinnamate, which prevents pyruvate transport into β -cells and mitochondria (25, 26), prevented the pyruvate-induced increase in INS-1 cell DNA synthesis with or without IGF-I (Fig. 1). Glutamine (10 mM) and leucine (10 mM) had no independent effect on cell $[^3\text{H}]$ thymidine incorporation into INS-1 cells, but in the added presence of 10 nM IGF-I there was a 3- to 4-fold increase in INS-1 cell DNA synthesis ($P \leq 0.05$; Fig. 1). However, when 10 mM leucine or 10 mM ketoisocaproate (a deaminated product of leucine) was combined with 10 mM glutamine (to activate glutamate dehydrogenase and increase intramitochondrial α -ketoglutarate) (26), a significant increase in INS-1 cell $[^3\text{H}]$ thymidine incorporation was observed (8- to 10-fold; $P \leq 0.05$) that further increased 25- to 30-fold with 10 nM IGF-I added ($P \leq 0.01$; Fig. 1).

Long chain FFA inhibit glucose- and IGF-I-induced β -cell DNA synthesis

It was examined whether FFAs would affect β -cell mitogenesis and/or provide a platform for growth factors to evoke a mitogenic response as previously observed (3, 4). It was found that in the absence of glucose or at glucose con-

centrations of 5 mM or more, long chain FFA ($>C_{12}$) tended to slightly increase INS-1 cell $[^3\text{H}]$ thymidine incorporation approximately 2-fold, but this was not statistically significant (data not shown). In contrast, it was found that FFAs inhibited glucose/IGF-I-induced INS-1 cell DNA synthesis (Fig. 2). FFAs of chain length C_8 to C_{18} [0.4 mM complexed to 1% (wt/vol) BSA] were incubated with INS-1 cells for 24 h at 15 mM glucose with or without 10 nM IGF-I. Linoleate ($C_{18:2}$), oleate ($C_{18:1}$), stearate ($C_{18:0}$), palmitate ($C_{16:0}$), myristate ($C_{14:0}$), laurate ($C_{12:0}$) significantly inhibited glucose-induced and glucose-dependent IGF-I-induced β -cell DNA synthesis by 95% or more ($P \leq 0.001$) compared with cells incubated in the absence of FFA (Fig. 2A). Caproate (C_{10}) also inhibited 15 mM glucose/IGF-I induced INS-1 cell $[^3\text{H}]$ thymidine incorporation, but to a lesser extent ($\sim 80\%$; $P \leq 0.005$; Fig. 2). Caprylate (C_8) partially inhibited 15 mM glucose-induced INS-1 cell $[^3\text{H}]$ thymidine incorporation ($38.5 \pm 3.3\%$; $n = 5$; $P \leq 0.05$), but had a negligible effect on glucose-dependent IGF-I induced β -cell DNA synthesis ($20.3 \pm 3.4\%$; $n = 5$; $P = \text{NS}$; Fig. 2).

In further experiments palmitate was used as a model FFA. Palmitate significantly inhibited β -cell DNA synthesis at 15 mM glucose with or without 10 nM IGF-I by 95% or more at a concentration of 0.2 mM or more complexed 1% BSA ($P \leq 0.001$; Fig. 3A). Titration inhibition curves indicated a K_{d50} of $86.0 \pm 9.4 \mu\text{M}$ palmitate (complexed 1% BSA; $n = 5$) for inhibition of 15 mM glucose-induced INS-1 cell DNA synthesis and a K_{d50} of $64.3 \pm 7.7 \mu\text{M}$ palmitate (complexed to 1% BSA; $n = 5$) for inhibition of 15 mM glucose-dependent





FIG. 2. Long chain FFA inhibit glucose- and IGF-I induced DNA synthesis in INS-1 cells. DNA synthesis was determined at 0, 3, or 15 mM glucose with or without 10 nM IGF-I (as controls) or at 15 mM glucose with or without 10 nM IGF-I in the additional presence of various acyl chain length FFAs (0.4 mM FFA complexed to 1% BSA) using a $[^3\text{H}]$ thymidine incorporation assay as described in *Materials and Methods*. All experiments were performed in triplicate on at least six independent occasions. The data are expressed as the fold increase above the control observation in the absence of glucose, IGF-I, and 0.2 mM palmitate/1% BSA and are depicted as the mean \pm SE ($n = 6$).

FIG. 3. Dose response and time course of palmitate-mediated inhibition of glucose- and IGF-I-induced DNA synthesis in INS-1 cells. DNA synthesis was determined at 15 mM glucose with or without 10 nM IGF-I over a 24-h period in the presence of various concentrations of palmitate (20–500 μ M) complexed to a constant 1% BSA (A) or at 0.2 mM palmitate complexed to 1% BSA for various periods between 2–24 h (B), using a [3 H]thymidine incorporation assay essentially as described in *Materials and Methods*. To include shorter periods during the time course assay, the amount of [3 H]thymidine added was doubled in a shorter radiolabeling period of 2 h. All experiments were performed in triplicate on at least six independent occasions. The data are expressed as the fold increase above the control observation in the absence of glucose, IGF-I, and 0.2 mM palmitate/1% BSA and are depicted as the mean \pm SE ($n \geq 6$).



IGF-I-induced INS-1 cell [3 H]thymidine incorporation (Fig. 3A). The time course for FFA-mediated inhibition of glucose-/IGF-I-induced INS-1 cell DNA synthesis was assessed using a slight modification of the 96-well plate [3 H]thymidine incorporation assay so as to assess early time points. Quiescent INS-1 cells were incubated in 15 mM glucose with or without 10 nM IGF-I in the added presence or absence of 0.2 mM palmitate complexed to 1% BSA for between 2–24 h, the last 2 h of which was in the presence of 10 μ Ci [3 H]thymidine/ml. For 0.2 mM palmitate inhibition of 15 mM glu-

cose-induced β -cell DNA synthesis, $t_{0.5} = 6.3 \pm 0.4$ h, and for inhibition of 15 mM glucose-dependent IGF-I-induced β -cell DNA synthesis, $t_{0.5} = 5.8 \pm 0.9$ h. (Fig. 3B).

Palmitate inhibition of INS-1 cell DNA synthesis was reversible. If palmitate was removed from the medium after 24-h exposure to 0.2 mM palmitate/1% BSA and INS-1 cells, then further incubated in the absence of FFA, inhibition glucose/IGF-I-induced β -cell DNA synthesis recovered to 80% of that in control cells by 24 h and was fully recovered by 36 h (data not shown). Bromopalmitate (0.4 mM com-


plexed to 1% BSA), an analog of palmitate that is not oxidized (26), significantly inhibited INS-1 cell [3 H]thymidine incorporation at 15 mM glucose with or without 10 nM IGF-I by 95% or more within 24 h ($P \leq 0.001$; data not shown), similar to that of palmitate (Figs. 2 and 3). This indicated that β -oxidation of FFA was not involved in FFA-induced inhibition of β -cell DNA synthesis. In contrast, methyl-palmitate (0.4 mM complexed to a constant 1% BSA), a modified form of palmitate that cannot form a coenzyme A (CoA) ester, only inhibited INS-1 cell [3 H]thymidine incorporation at 15 mM glucose with or without 10 nM IGF-I by 30% within 24 h ($P = \text{NS}$; data not shown). This latter observation suggested that formation of a fatty acyl-CoA moiety was necessary for FFA-mediated inhibition of glucose/IGF-I induced β -cell DNA synthesis. As ceramide can be derived from palmitoyl-CoA (27, 28), it was examined whether ceramide would affect glucose-induced and/or glucose-dependent IGF-I-induced INS-1 cell DNA synthesis in a similar fashion to that by FFA. However, addition of neither 10 μM C2-ceramide (*N*-acetyl-D-erythro-sphingosine) nor 10 μM C2-dihydroceramide (di-

hydro-*N*-acetyl-D-erythro-sphingosine; a biologically inactive analog of C2-ceramide) had any effect on glucose-induced or glucose-dependent IGF-I-induced INS-1 cell [3 H]thymidine incorporation.

FFA do not inhibit glucose or IGF-I activation of IRS-1/2 or Shc in INS-1 cells

Activation of IRS-mediated mitogenic signaling transduction pathways by glucose with or without IGF-I in INS-1 cells that were previously exposed to 0.4 mM palmitate/1% BSA (or 1% BSA alone as a control) for 24 h was investigated using coimmunoprecipitation and immunoblot analysis. Immunoprecipitation of the 85-kDa regulatory subunit of PI3'-K followed by immunoblot analysis for IRS-1 (Fig. 4A) or IRS-2 (Fig. 4B) revealed a significant increased association of PI3'-K with IRS-1 and IRS-2 instigated by stimulatory 15 mM glucose and IGF-I, similar to that previously observed (3, 4). However, palmitate had no adverse affect on glucose/IGF-I-induced PI3'-K/IRS-1 or PI3'-K/IRS-2 interaction (Fig. 4, A

FIG. 4. Long chain FFA does not affect glucose- and IGF-I induced association of IRS-1/2 PI3'-K, Grb2, and mSOS. Recruitment of PI3'-K and Grb2/mSOS to an IRS-1/2 signaling complex was assessed by coimmunoprecipitation analysis as outlined in *Materials and Methods*. Essentially, INS-1 cells were then stimulated with 3 or 15 mM glucose with or without 10 nM IGF-I in the presence or absence 0.2 mM palmitate/1% BSA for 10 min, lysed, then subjected to immunoprecipitation (IP) with antiserum against the p85 regulatory subunit of PI3'-K. Immunoprecipitates were then immunoblot (IB) analyzed with IRS-1 (A), IRS-2 (B), mSOS (C), mGrb2 (D), and p85 PI3'-K (E) antibodies. An example blot for such coimmunoprecipitation analysis is shown.



and B). Likewise, immunoblotting of the p85 PI3'-K immunoprecipitates with antiserum recognizing mSOS (Fig. 4C) or Grb2 (Fig. 4D) indicated an increased association of mSOS and Grb2 to a PI3'-K/IRS signaling complex by 15 mM glucose, which was further increased in the presence of 10 nM IGF-I as previously described (3, 4). However, as for IRS-1/2 association with PI3'-K, palmitate had no adverse effect on glucose-induced or glucose-dependent IGF-I-induced association of Grb2/mSOS to the IRS signaling complex in β -cells (Fig. 4, C and D). The specific nature of this glucose/IGF-I-induced Grb2/mSOS, IRS-1, and IRS-2 interaction with PI3'-K was indicated, in that p85 PI3'-K immunoblot analysis of PI3'-K immunoprecipitates revealed that an equivalent amount of PI3'-K was present in each sample (Fig. 4E). In additional experiments, it was found that 15 mM glucose and IGF-I were able to significantly promote Shc association with Grb2/mSOS similar to that previously described (3, 4). However, addition of 0.4 mM palmitate/1% BSA for 24 h had no effect on the glucose/IGF-I-induced association of Grb2/mSOS to Shc (data not shown).


FFA do not inhibit glucose or IGF-I activation of MAPKs in INS-1 cells

The activation of mSOS, by its Grb2-mediated association with tyrosine phosphorylated IRS and/or Shc, results in

downstream activation of Ras, which, in turn, stimulates Raf-1 serine kinase activity (5). Raf-1 then activates MEK, which, in turn, activates MAPK (Erk-1 and -2 isoforms) by serine phosphorylation (5). Activated MAPK can be detected with specific antiserum that only recognizes the phosphorylation-activated forms of Erk-1 and -2 (3, 4). Stimulatory 15 mM glucose independently increased Erk-1 and -2 phosphorylation activation above zero glucose, which was increased further in the presence of 10 nM IGF-I (Fig. 5A; $P \leq 0.01$). IGF-I also increased Erk-1 and -2 activation at a lower 3 mM glucose (Fig. 5A; $P \leq 0.05$). The glucose/IGF-I-induced phosphorylation activation of Erk-1 and -2 was unaffected by the presence of 0.4 mM palmitate/1% BSA (Fig. 5A). The total amount of Erk-1 and 2 in INS-1 cells, as ascertained by immunoblot analysis with antisera recognizing both active and inactive forms of Erk-1 and -2, was not significantly altered by glucose, IGF-I, or FFA treatment (Fig. 5A).

It was also examined whether FFA exerted an inhibitory effect on β -cell DNA synthesis via activation of stress kinase signaling pathways, which include other members of the MAPK family, such as p38 and JNK-1/-2 (29). As for Erk1 and -2, activation of p38 and JNK-1 and -2 can be detected with specific antiserum that specifically recognizes the phosphorylation-activated forms of these protein kinases (30). Phosphorylation activation of p38 was greatest in the absence

FIG. 5. Long chain FFA does not affect glucose- and IGF-I stimulated phosphorylation activation of MAPK, Erk-1/2, and p38 or p70^{S6K} in INS-1 cells. INS-1 cells, incubated in the presence or absence of 0.2 mM palmitate complexed to 1% BSA for 24 h, were stimulated with 3 or 15 mM glucose with or without 10 nM IGF-I for 10 min (for Erk-1/2 and p38 analysis) or 30 min (for p70^{S6K} analysis), then analyzed for phosphorylation activation of Erk-1/2, p38, and p70^{S6K} by specific immunoblot analysis as described in *Materials and Methods*. Representative immunoblot (IB) analysis of activated phospho-Erk-1/2 and total Erk-1/2 (A) and activated phospho-p38 and total p38 (B) are shown. A representative immunoblot for p70^{S6K} is shown (C), where phosphorylated forms of p70^{S6K} become retarded on SDS-PAGE analysis, and these multiphosphorylated p70^{S6K} forms are indicated by the arrows.



of glucose (Fig. 5B). At 3 mM glucose, a p38 phosphorylation state was reduced by 40–50% compared with zero glucose, and by more than 90% at 15 mM glucose (Fig. 5B). As such, the effect of glucose on p38 phosphorylation activation inversely correlated with glucose-induced activation of Erk-1 and -2 (Fig. 5A). No significant effect of IGF-I or 0.4 mM palmitate/1% BSA was observed on phosphorylation activation of p38 at any glucose concentration (Fig. 5B). Total p38 in INS-1 cells, as ascertained by immunoblot analysis with antisera recognizing both active and inactive forms of p38, was not significantly altered by glucose, IGF-I, or FFA treatment (Fig. 5B). Phosphorylation activation of JNK-1 and -2 was also assessed and was found to follow the same pattern as that for p38. JNK-1 and -2 phosphorylation inversely correlated to increasing glucose concentration. As for p38, IGF-I and FFA had no effect on the phosphorylation state of JNK-1 and -2 (data not shown).

FFA do not inhibit glucose or IGF-I activation of PI3'-K in INS-1 cells

PI3'-K activity was assessed in PI3'-K p85 immunoprecipitates as previously described (21, 22), derived from INS-1 cells previously exposed for 24 h with either 0.4 mM palmitate/1% BSA or 1% BSA, then incubated for 15 min at 3 or 15 mM glucose (with or without 10 nM IGF-I). An equivalent amount of p85 regulatory subunit of PI3'-K was immunoprecipitated from the variously treated INS-1 cell lysates (Fig. 6, upper panel). At 3 mM glucose, PI3'-K activity was increased 3.0 ± 0.5 -fold ($n = 3$; $P \leq 0.05$) above that at zero glucose, and in the added presence of IGF-I was further increased 4.6 ± 0.7 -fold ($n = 3$; $P \leq 0.05$; Fig. 6). At a stimulatory 15 mM glucose, PI3'-K activity was increased 4.7 ± 0.6 -fold ($n = 3$; $P \leq 0.05$) above that at zero glucose, and in the added presence of IGF-I was further increased 7.2 ± 0.9 -fold ($n = 3$; $P \leq 0.02$; Fig. 6). The presence of 0.4 mM palmitate/1% BSA had

no effect on glucose- or IGF-I-induced activation of PI3'-K activity.

FFA inhibited glucose and IGF-I activation of PKB in INS-1 cells

PKB activity was assessed in PKB immunoprecipitates *in vitro* using an assay kit from New England Biolabs, Inc., based on a recombinant GSK3 protein substrate and subsequent detection of PKB-mediated GSK3 phosphorylation by specific phospho-GSK3 immunoblot analysis (Fig. 7, middle panel). Total PKB was immunoprecipitated from INS-1 cells previously exposed for 24 h to either 0.4 mM palmitate/1% BSA or 1% BSA, then incubated for 15 min at 3 or 15 mM glucose (with or without 10 nM IGF-I). An equivalent amount of PKB was immunoprecipitated from the variously treated INS-1 cell lysates (Fig. 7, upper panel). Extended electrophoresis and subsequent immunoblot analysis revealed that PKB α , PKB β , and, to a lesser extent, PKB γ isoforms were present in β -cells (data not shown). At 3 mM glucose, PKB activity increased 3.6 ± 0.4 -fold ($n = 6$; $P \leq 0.01$) above that at zero glucose, and in the added presence of IGF-I was further increased 5.6 ± 0.5 -fold ($n = 6$; $P \leq 0.005$; Fig. 7). At a stimulatory 15 mM glucose, PKB activity increased 5.8 ± 0.5 -fold ($n = 6$; $P \leq 0.01$) above that at zero glucose, and in the added presence of IGF-I was further increased 7 ± 0.8 -fold ($n = 6$; $P \leq 0.01$; Fig. 7). However, in the presence of 0.4 mM palmitate/1% BSA, activation of PKB at 3 mM glucose was significantly reduced by 25% ($P \leq 0.05$) in the absence of IGF-I and by 40% ($P \leq 0.01$) in the presence of IGF-I (Fig. 7). The addition of 0.4 mM palmitate/1% BSA reduced 15 mM glucose-induced PKB activity by 28% ($P \leq 0.05$), but had a more marked effect on IGF-I-induced PKB activation at 15 mM glucose, where PKB activity was inhibited by 52% ($P \leq 0.01$; Fig. 7).

FIG. 6. Long chain FFA does not affect glucose- and IGF-I-stimulated PI3'-K activity in INS-1 cells. INS-1 cells, incubated in the presence or absence of 0.2 mM palmitate complexed to 1% BSA, were stimulated with 3 or 15 mM glucose with or without 10 nM IGF-I for 10 min. INS-1 cell lysates were then subjected to immunoprecipitation (IP) with antiserum against the p85 regulatory subunit of PI3'-K. PI3'-K activity was measured in p85 immunoprecipitates as outlined in *Materials and Methods*. Equivalent p85 was immunoprecipitated between samples as assessed by immunoblot analysis of p85 immunoprecipitates, of which a representative immunoblot is shown. The data are expressed as the fold increase above the control observation in the absence of glucose, IGF-I, and 0.2 mM palmitate/1% BSA and are depicted as the mean \pm SE ($n \geq 3$).





FIG. 7. Long chain FFA partly inhibit glucose/IGF-I-stimulated PKB activity in INS-1 cells. INS-1 cells, incubated in the presence or absence of 0.2 mM palmitate complexed to 1% BSA, were stimulated with 3 or 15 mM glucose with or without 10 nM IGF-I for 10 min. INS-1 cell lysates were then subjected to immunoprecipitation (IP) with anti-serum against total PKB. PKB activity was then measured in PKB immunoprecipitates, as outlined in Materials and Methods, using recombinant GSK3 as a substrate and phosphorylation analysis with specific phospho-GSK immunoblot analysis (of which a representative phospho-GSK immunoblot is shown). Equivalent PKB was immunoprecipitated between samples, as assessed by immunoblot analysis of PKB immunoprecipitates, of which a representative immunoblot is shown. The data are expressed as the fold increase above the control observation in the absence of glucose, IGF-I, and 0.2 mM palmitate/1% BSA and are depicted as the mean \pm SE ($n \geq 6$).



FFA do not inhibit glucose or IGF-I activation of $p70^{S6K}$ in INS-1 cells

$p70^{S6K}$ is activated downstream of $PI3'K/PKB$ activation (31). Phosphorylation activation of $p70^{S6K}$ occurs on multiple sites, so $p70^{S6K}$ phosphorylation can be detected on immunoblot analysis by apparent electrophoresis mobility retardation (32). INS-1 cells previously exposed for 24 h to either 0.4 mM palmitate/1% BSA or 1% BSA were then incubated for 30 min at 3 mM or stimulatory 15 mM glucose (with or without 10 nM IGF-I). Immunoblot analysis with $p70^{S6K}$ -specific antiserum indicated that phosphorylation activation of $p70^{S6K}$ in β -cells was not detected in the absence or presence of 3 mM glucose with or without IGF-I (Fig. 5C), similar to that previously observed (3, 4). However, phosphorylation activation of $p70^{S6K}$ in response to 15 mM glucose was observed, which was further increased in the presence of IGF-I (Fig. 5C). The presence of 0.4 mM palmitate/1% BSA had no effect on glucose-induced or glucose-dependent IGF-I-induced phosphorylation activation of $p70^{S6K}$.

FFA-induced activation of $PKC\zeta$ INS-1 cells


$PKC\zeta$ activity was assessed in $PKC\zeta$ immunoprecipitates *in vitro* as previously described (23). Total $PKC\zeta$ was immunoprecipitated from INS-1 cells previously exposed for 24 h to either 0.4 mM palmitate/1% BSA or 1% BSA, then incubated for 15 min at 3 or 15 mM glucose (with or without 10 nM IGF-I). An equivalent amount of $PKC\zeta$ was immunoprecipitated from variously treated INS-1 cell lysates (Fig. 8, upper panel). In the absence of glucose, but in the presence of 0.4 mM palmitate/1% BSA, $PKC\zeta$ activity was elevated 5.1 ± 0.6 -fold ($n = 7$; $P \leq 0.005$) above that in the presence of 1% BSA only (Fig. 8). This indicated increased activity of $PKC\zeta$ during the prior 24-h incubation in the presence of FFA. For INS-1 cells incubated in the absence of FFA, 3 mM glucose increased $PKC\zeta$ activity $3.2 \pm$

0.4-fold ($n = 6$; $P \leq 0.05$) above that at zero glucose, and in the added presence of IGF-I it was further increased to 4.6 ± 0.6 -fold ($n = 6$; $P \leq 0.05$; Fig. 8). However, this modest incremental increase in $PKC\zeta$ activity induced by IGF-I at 3 mM glucose was not statistically significant. In INS-1 cells exposed to 0.4 mM palmitate/1% BSA and incubated at 3 mM glucose for 15 min, $PKC\zeta$ activity was significantly enhanced 7.5 ± 0.9 -fold ($n = 5$; $P \leq 0.02$) above that at zero glucose, 2.3-fold higher than INS-1 cells incubated in the absence of FFA. Likewise, at 3 mM glucose and 10 nM IGF-I, 0.4 mM palmitate/1% BSA treatment of INS-1 cells, $PKC\zeta$ activity was significantly enhanced 11.3 ± 1.7 -fold ($n = 5$; $P \leq 0.05$) above that at zero glucose, 2.5-fold higher than equivalent INS-1 cells incubated in the absence of FFA. At a stimulatory 15 mM glucose, $PKC\zeta$ activity was increased 9.6 ± 1.5 -fold ($n = 6$; $P \leq 0.05$) above that at zero glucose, and in the added presence of IGF-I was further increased to 10.4 ± 1.1 -fold ($n = 6$; $P \leq 0.02$; Fig. 8). As at 3 mM glucose, the slight incremental increase in $PKC\zeta$ activity induced by IGF-I at 15 mM glucose was not statistically significant. Nonetheless, in the presence of 0.4 mM palmitate/1% BSA, activation of $PKC\zeta$ by 15 mM glucose was significantly enhanced 13.1 ± 1.2 -fold ($n = 5$; $P = 0.02$) above that at zero glucose, which was 36% higher than the level in INS-1 cells incubated in the absence of FFA. Likewise, $PKC\zeta$ activation by 15 mM glucose and 10 nM IGF-I in the presence of 0.4 mM palmitate/1% BSA-treated INS-1 cells was significantly enhanced 15.3 ± 1.8 -fold ($n = 5$; $P \leq 0.05$) above that at zero glucose, which was 47% higher than the level in equivalent INS-1 cells incubated in the absence of FFA (Fig. 8).

Discussion

Glucose is a major factor that regulates pancreatic β -cell mitogenesis (1, 2). It has recently been shown that the effect of IGF-I and GH to increase β -cell mitogenesis was depen-

FIG. 8. Long chain FFA chronically increase PKC ζ activity in INS-1 cells. INS-1 cells, incubated in the presence or absence of 0.2 mM palmitate complexed to 1% BSA, were incubated in the absence of glucose or with 3 or 15 mM glucose with or without 10 nM IGF-I for 15 min. INS-1 cell lysates were then subjected to immunoprecipitation (IP) with antiserum against PKC ζ . PKC ζ activity was measured in the immunoprecipitates as outlined in *Materials and Methods*. Equivalent PKC ζ was immunoprecipitated between samples, as assessed by immunoblot analysis of PKC ζ immunoprecipitates, of which a representative immunoblot is shown. The data are expressed as the fold increase above the control observation in the absence of glucose, IGF-I, and 0.2 mM palmitate/1% BSA and are depicted as the mean \pm SE (n \geq 6).



dent on glucose metabolism in the physiologically relevant concentration range (6–18 mM) (3, 4). Therefore, it is conceivable that the pancreatic β -cell population is flexible and can adapt to the nutritional status of the organism (34), similar to the transient increase in β -cell mass that occurs during pregnancy (35). In this study we have examined whether certain intermediates of glucose metabolism and alternative metabolic fuels are capable of stimulating β -cell DNA synthesis independently as well as providing the necessary metabolic environment so that IGF-I can promote β -cell mitogenesis. Pyruvate, a product of glycolysis in β -cells, independently increased β -cell DNA synthesis at similar concentrations previously shown to specifically increase proinsulin biosynthesis and insulin secretion (26) and also enabled IGF-I to cause a marked increase in β -cell mitogenesis. Likewise, the combination of glutamine and leucine added to the medium to generate intracellular α -ketoglutarate (36) independently increased β -cell DNA synthesis and provided the environment for IGF-I-induced β -cell mitogenesis, similar to the effect of the glutamine/leucine combination on (pro)insulin synthesis and secretion (26). As both pyruvate and glutamate/leucine are used as mitochondrial fuels in β -cells, these data suggest that β -cell mitochondrial metabolism, downstream of glycolysis, is important for generating secondary coupling signals for glucose-induced β -cell DNA synthesis and for providing the permissive environment for IGF-I-induced β -cell mitogenesis.

However, not all metabolic fuels act as β -cell mitogens or provide a platform of growth factors to induce β -cell mitogenesis. In the absence of glucose (or at \leq 5 mM glucose) FFAs were observed to have only a modest effect on INS-1 cell DNA synthesis compared with that of 15 mM glucose. Similar observations of the effect of FFA on β -cell mitogenesis have been previously made in islets (37), and INS-1 cells (38). In

this study it was found that long chain ($>C_{10}$) FFA prevented 15 mM glucose-induced and glucose-dependent IGF-I-induced β -cell DNA synthesis within a 24-h period ($t_{0.5} = \sim 6$ h). FFA-mediated inhibition of β -cell DNA synthesis occurred at a relatively low concentration of FFA ($K_{i0.5} = \sim 60$ – $90 \mu\text{M}$ FFA complexed to 1% BSA) and was reversible upon removal of the FFA. Thus, it was unlikely that FFA-mediated inhibition of β -cell mitogenesis was due to a non-specific detergent-like effect. FFA-induced inhibition of β -cell DNA synthesis might have been acting via FFA-derived intracellular ceramide formation, but this was unlikely, because ceramide had no effect on glucose/IGF-I-induced β -cell DNA synthesis. This would be consistent with the observation that both palmitate and oleate inhibited glucose/IGF-I induced β -cell mitogenesis, as ceramide is derived from palmitoyl-CoA, but not directly from oleoyl-CoA (39). Notwithstanding, long chain fatty acyl-CoA moieties were probably involved, as methyl-palmitate (which cannot form a CoA ester) was not as effective as other FFAs in mediating the inhibition of glucose/IGF-I-induced β -cell DNA synthesis. However, FFA-mediated inhibition of β -cell DNA synthesis was not due to changes in FFA oxidation, as a nonmetabolizable FFA analog (bromopalmitate) was also effective at inhibiting glucose/IGF-I-induced β -cell DNA synthesis. Moreover, it was found that in INS-1 cells that were incubated for 24 h in the presence of FFA (0.4 mM palmitate or oleate complexed to 1% BSA), the rate of glucose oxidation (at either 3 or 15 mM glucose) was unaffected by FFA (data not shown), as previously shown in pancreatic islets (40). Therefore, FFA were unlikely to inhibit glucose metabolism that, in turn, would affect the glucose-dependent aspect of growth factor-induced β -cell mitogenesis (3, 4).

IRS-mediated signal transduction in INS-1 cells (particularly via IRS-2) (9–11) has previously been shown to be

necessary for glucose-induced and glucose-dependent IGF-I-induced β -cell DNA synthesis (3, 4). It was investigated whether FFA would interfere with glucose/IGF-I-induced signal transduction via IRS in a manner that correlated with FFA-mediated inhibition of glucose/IGF-I-induced β -cell DNA synthesis. Using palmitate as a model, it was found that FFA did not affect glucose/IGF-I-induced recruitment of PI3'-K or Grb2/mSOS to IRS-1/2, recruitment of Grb2/mSOS to Shc, activation of PI3'-K activity, or phosphorylation activation of Erk-1/2 or p70^{S6K}. The stress kinases p38 and JNK-1/2 were phosphorylation activated by decreasing glucose concentrations, but were unaffected by FFA. Thus, it was unlikely that p38 or JNK-1/2 was involved in FFA-mediated inhibition of glucose/IGF-I-induced β -cell mitogenesis. In contrast, FFA significantly inhibited glucose/IGF-I-induced activation of PKB activity. However, it should be noted that FFA-mediated inhibition of PKB activity in β -cells was partial, and downstream glucose/IGF-I-induced phosphorylation activation of p70^{S6K} was not affected by FFA. Nonetheless, although residual PKB activity in the presence of FFA was sufficient to promote full activation of p70^{S6K}, it is possible that phosphorylation of alternative protein substrates by PKB is inhibited in the presence of FFA, which, in turn, could lead to decreased β -cell mitogenesis (41–43).

It was also found that FFA activated PKC ζ in INS-1 cells during a 24-h exposure, independently of glucose or IGF-I. In INS-1 cells previously exposed to FFA for 24 h, subsequent glucose/IGF-I-stimulated PKC ζ activity was additive to the FFA-induced PKC ζ activity. This raises the possibility that glucose/IGF-I and FFA activate β -cell PKC ζ via distinct mechanisms. Indeed, PKC ζ can be directly activated by both FFA, and phosphatidylinositol-3,4,5-trisphosphate can be generated by glucose/IGF-I induced activation of PI3'-K (44). Also, PKC ζ activity can be further increased via phosphorylation by phosphoinositide-dependent protein kinase-1 (PDK-1), an enzyme that also lies downstream of PI3'-K (45, 46). Thus, PKC ζ activity can be chronically activated by FFA-treated β -cells and further enhanced by increased glucose/IGF-I levels acutely. However, signaling proteins such as PKC ζ are only transiently activated under normal circumstances (44). As such, chronic FFA-induced activation of PKC ζ may lead to an abnormal prolonged phosphorylation state of certain protein substrates that could, in turn, lead to β -cell dysfunction, including an antagonism of glucose-induced mitogenesis. Interestingly, it has been shown that chronic activation of PKC ζ can inhibit PKB activity (47, 48), and one might speculate that chronic FFA-induced activation of PKC ζ contributed to FFA-mediated inhibition of glucose/IGF-I-induced activation of PKB in β -cells. However, although it is intriguing to contemplate that FFA-mediated inhibition of glucose/IGF-I-induced activation of PKB and/or chronic activation of PKC ζ can contribute to FFA-induced inhibition of β -cell DNA synthesis, this needs to be demonstrated more directly by further experimentation. For instance, if this scenario is correct, one might predict that expression of a dominant negative PKB and/or constitutively active PKC ζ would mimic FFA-mediated inhibition of glucose/IGF-I-induced

β -cell DNA synthesis. Notwithstanding, FFA-mediated inhibition and/or chronic activation of other signal elements downstream of IRS, or in alternative signal transduction pathways cannot, for the moment, be ruled out as a mechanism for preventing glucose/IGF-I-induced β -cell mitogenesis.

It is currently thought that peripheral insulin resistance in obesity is compensated by an increase in pancreatic β -cell mass and consequential increased insulin production (8). However, a failure of β -cell mass to compensate for insulin resistance results in type II diabetes (6, 7, 11). It has previously been shown that hyperglycemia and hyperlipidemia contribute to β -cell dysfunction (6–8, 14). Chronic exposure of high concentrations of glucose can induce β -cell death (49) despite the common observation of glucose-induced β -cell growth (1, 2). It has also been proposed that FFA and triglyceride accumulation in β -cells derived from hyperlipidemia in obesity-linked type II diabetes contributes to β -cell dysfunction and reduction of β -cell mass (6, 8). Indeed, it has been previously shown that FFA and subsequent intracellular ceramide formation instigated β -cell apoptosis (8). The FFA-induced inhibition of glucose/IGF-I-induced β -cell mitogenesis outlined in this study (via a mechanism independent of ceramide) would additionally contribute to a FFA-induced decrease in β -cell mass and a failure to compensate for peripheral insulin resistance, which are keys to the pathogenesis of type II diabetes (6, 8). It is possible that FFA-induced inhibition of glucose/IGF-I-induced β -cell mitogenesis could be mediated by FFA-induced inhibition of PKB activation and/or chronic activation of PKC ζ , although further experiments will be required to substantiate this observation. However, it should be noted that FFA also inhibit PKB (50, 51) and chronically activate certain PKC isoforms (52, 53) in skeletal muscle cells that, in turn, contribute to peripheral insulin resistance. Thus, similar adverse affects of FFA on insulin signal transduction in peripheral tissues and mitogenic signaling pancreatic β -cells both contribute to the pathogenesis of obesity-linked type II diabetes.

References

1. Swenne I 1992 Pancreatic β -cell growth and diabetes mellitus. *Diabetologia* 35:193–201
2. Scharfmann R, Czernichow P 1996 Differentiation and growth of pancreatic β cells. *Diabet Metab* 22:223–228
3. Hügl SR, White MF, Rhodes CJ 1998 IGF-I stimulated pancreatic β -cell growth is glucose dependent: synergistic activation of IRS-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. *J Biol Chem* 273:17771–17779
4. Cousin SP, Hügl SR, Myers MG, White MF, Reifel-Miller A, Rhodes CJ 1999 Stimulation of pancreatic β -cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription-5 (STAT5) with no crosstalk to insulin-receptor substrate (IRS) mediated signalling. *Biochem J* 344:649–658
5. Benito M, Valverde AM, Lorenzo M 1996 IGF-I: a mitogen also involved in differentiation processes in mammalian cells. *Int J Biochem Cell Biol* 28:499–510
6. Unger RH 1995 Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. *Diabetes* 44:863–870
7. Ferrannini E 1998 Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. *Endocr Rev* 19:477–490
8. Unger RH 1998 How obesity causes diabetes in Zucker diabetic fatty rats. *Trends Endocrinol Metab* 7:276–282
9. Schuppert GT, Pons S, Hügl SR, Aiello LP, King GL, White MF, Rhodes CJ 1998 A specific increased expression of IRS-2 in pancreatic β -cell lines is involved in mediating serum stimulated β -cell growth. *Diabetes* 47:1074–1084
10. Withers DJ, Gutierrez JS, Towery H, Ren J-M, Burks DJ, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF 1997 Disruption of IRS-2 causes type-2 diabetes in mice. *Nature* 391:900–904

11. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF 1999 Irs-2 coordinates IGF-I receptor-mediated β -cell development and peripheral insulin signalling. *Nat Genet* 23:32–40
12. Elbein SC 1997 The genetics of human noninsulin-dependent (type 2) diabetes mellitus. *J Nutr* 127:1891S–1896S
13. Bektas A, Warram JH, White MF, Krolewski AS, Doria A 1999 Exclusion of insulin receptor substrate 2 (IRS-2) as a major locus for early-onset autosomal dominant type 2 diabetes. *Diabetes* 48:640–642
14. Polonsky KS 1999 Evolution of beta-cell dysfunction in impaired glucose tolerance and diabetes. *Exp Clin Endocrinol Diabetes [Suppl 4]* 107:S124–S127
15. Boden G 1997 Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. *Diabetes* 46:3–10
16. Buettner R, Newgard CB, Rhodes CJ, O'Doherty RM 2000 Correction of diet-induced hyperglycemia, hyperinsulinemia, and skeletal muscle insulin resistance by sustained, moderate elevation of plasma leptin. *Am J Physiol* 278:E563–E569
17. Myers MG, White MF 1996 Insulin signal transduction and IRS proteins. *Annu Rev Pharmacol Toxicol* 36:615–658
18. Yenush L, Zanella C, Uchida T, Bernal D, White MF 1998 The pleckstrin homology and phosphotyrosine binding domains of insulin receptor substrate 1 mediate inhibition of apoptosis by insulin. *Mol Cell Biol* 18:6784–6794
19. Asfari M, Janjic D, Meda P, Guodong L, Halban PA, Wollheim CB 1992 Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. *Endocrinology* 130:167–178
20. Frodin M, Sekine N, Roche E, Filloux C, Prentki M, Wollheim CB, Van Obberghen E 1995 Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting beta-cell line, INS-1. *J Biol Chem* 270:7882–7889
21. Myers MGJ, Grammer TC, Wang LM, Sun XJ, Pierce JH, Blenis J, White MF 1994 Insulin receptor substrate-1 mediates phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. *J Biol Chem* 269:28783–28789
22. Frevert EU, Kahn BR 1997 Differential effects of constitutively active phosphatidylinositol 3-kinase on glucose transport, glycogen synthase activity and DNA synthesis in 3T3-L1 adipocytes. *Mol Cell Biol* 17:198–198
23. Bandyopadhyay G, Standaert ML, Zhao L, Yu B, Avignon A, Galloway L, Karnam P, Moscat J, Farese RV 1997 Activation of protein kinase C (α , β , and ζ) by insulin in 3T3/L1 cells. Transfection studies suggest a role for PKC- ζ in glucose transport. *J Biol Chem* 272:2551–2558
24. Prentki M, Tornheim K, Corkey BE 1997 Signal transduction mechanisms in nutrient-induced insulin secretion. *Diabetologia [Suppl 2]* 40:S32–S41
25. Juntti-Berggren L, Civelek VN, Berggren PO, Schultz V, Corkey BE, Tornheim K 1994 Glucose-stimulated increase in cytoplasmic pH precedes increase in free Ca^{2+} in pancreatic β -cells. A possible role for pyruvate. *J Biol Chem* 269:14391–14395
26. Skelly RH, Bollheimer LC, Wicksteed BL, Corkey BE, Rhodes CJ 1997 A distinct difference in the metabolic stimulus-response coupling pathways for regulating proinsulin biosynthesis and insulin secretion that lies at the level of a requirement for fatty acyl moieties. *Biochem J* 331:553–561
27. Shimabukuro M, Zhou YT, Levi M, Unger RH 1998 Fatty acid-induced β cell apoptosis: a link between obesity and diabetes. *Proc Natl Acad Sci USA* 95:2498–2502
28. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, Unger RH 1998 Lipopapoptosis in β -cells of obese prediabetic *fa/fa* rats. Role of serine palmitoyltransferase overexpression. *J Biol Chem* 273:32487–3290
29. Ichijo H 1999 From receptors to stress-activated MAP kinases. *Oncogene* 18:6087–6093
30. Guan Z, Buckman SY, Springer LD, Morrison AR 1999 Both p38 α (MAPK) and JNK/SAPK pathways are important for induction of nitric-oxide synthase by interleukin-1 β in rat glomerular mesangial cells. *J Biol Chem* 274:36200–36206
31. Kadowaki T, Tobe K, Honda-Yamamoto R, Tamemoto H, Kaburagi Y, Momomura K, Ueki K, Takahashi Y, Yamauchi T, Akanuma Y, Yazaki Y 1996 Signal transduction mechanism of insulin and insulin-like growth factor-1. *Endocr J* 43:S33–S41
32. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR 1994 Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70S6 kinase, DNA synthesis, and glucose transporter translocation. *Mol Cell Biol* 17:4902–4911
33. Standaert ML, Galloway L, Karnam P, Bandyopadhyay G, Moscat J, Farese RV 1997 Protein kinase C- ζ as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. *J Biol Chem* 272:30075–30082
34. Bonner-Weir S 1994 Regulation of pancreatic β -cell mass in vivo. *Recent Prog Horm Res* 49:91–104
35. Sorenson RL, Brelje TC 1997 Adaptation of islets of Langerhans to pregnancy: β -cell growth, enhanced insulin secretion and the role of lactogenic hormones. *Horm Metab Res* 29:301–307
36. Lenzen S, Schmidt W, Panten U 1985 Transamination of neutral amino acids and 2-keto acids in pancreatic B-cell mitochondria. *J Biol Chem* 260:12629–12634
37. Milburn JL, Hirose H, Lee YH, Nagasawa A, Ogawa M, Ohneda H, Beltrandel Rio H, Newgard CB, Johnson JH, Unger RH 1995 Pancreatic β -cells in obesity: evidence for induction of functional morphologic and metabolic abnormalities by increased long-chain fatty acids. *J Biol Chem* 270:1295–1299
38. Roche E, Buteau J, Aniento I, Reig JA, Soria B, Prentki M 1999 Palmitate and oleate induced the immediate-early response genes *c-fos* and *nur-77* in the pancreatic β cell line, INS-1. *Diabetes* 48:2001–2014
39. Merrill AHJ, Wang E, Mullins RE 1988 Kinetics of long-chain (sphingoid) base biosynthesis in intact LM cells: effects of varying the extracellular concentrations of serine and fatty acid precursors of this pathway. *Biochemistry* 27:340–345
40. Liu YQ, Tornheim K, Leahy JL 1999 Glucose-fatty acid cycle to inhibit glucose utilization and oxidation is not operative in fatty-acid cultured islets. *Diabetes* 48:1747–1753
41. Rena G, Guo S, Cichy SC, Unterman TG, Cohan P 1999 Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. *J Biol Chem* 274:17179–17183
42. Dufner A, Andjelkovic M, Burgering BM, Hemmings BA, Thomas G 1999 Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. *Mol Cell Biol* 9:4525–4534
43. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA 1995 Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* 378:785–789
44. Liu J-P 1996 Protein kinase C and its substrates. *Mol Cell Endocrinol* 116:1–29
45. Dong LQ, Zhang RB, Langlais P, He H, Clark M, Zhu L, Liu F 1999 Primary structure, tissue distribution, and expression of mouse phosphoinositide-dependent protein kinase-1, a protein kinase that phosphorylates and activates protein kinase C ζ . *J Biol Chem* 274:8117–8122
46. Chou MM, Hou W, Johnson J, Graham LK, Lee MH, Chen CS, Newton AC, Schaffhausen BS, Tokar A 1998 Regulation of protein kinase C ζ by PI 3-kinase and PDK-1. *Curr Biol* 8:1069–1077
47. Doornbos RP, Theelen M, van der Hoeven PC, van Blitterswijk WJ, Verkleij J, van Bergen en Henegouwen PM 1999 Protein kinase C ζ is a negative regulator of protein kinase B activity. *J Biol Chem* 274:8589–8596
48. Barthel A, Nakatani K, Dandekar AA, Roth RA 1998 Protein kinase C modulates the insulin-stimulated increase in Akt1 and Akt3 activity in 3T3-L1 adipocytes. *Biochem Biophys Res Commun* 43:509–513
49. Donath MY, Gross DJ, Cerasi E, Kaiser N 1999 Hyperglycemia-induced β -cell apoptosis in pancreatic islets of *Psammomys obesus* during development of diabetes. *Diabetes* 48:738–744
50. Storz P, Doppler H, Wernig A, Pfizenmaier K, Muller G 1999 Cross-talk mechanisms in the development of insulin resistance of skeletal muscle cells palmitate rather than tumour necrosis factor inhibits insulin-dependent protein kinase B (PKB)/Akt stimulation and glucose uptake. *Eur J Biochem* 266:17–25
51. Schmitz-Peiffer C, Craig DL, Biden TJ 1999 Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. *J Biol Chem* 274:24202–24210
52. Laybutt DR, Schmitz-Peiffer C, Saha AK, Ruderman NB, Biden TJ, Kraegen EW 1999 Muscle lipid accumulation and protein kinase C activation in the insulin-resistant chronically glucose-infused rat. *Am J Physiol* 277:E1070–E1076
53. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI 1999 Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade. *Diabetes* 48:1270–1274